Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries

Human Vaccines

Volumn 7, Issue 5, 2011, Pages 506-510

  El Khoury, Antoine C ^a   Mast, T Christopher ^a   Ciarlet, Max ^b   Markson, Leona E ^a   Goveia, Michelle G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Asia; Deaths; Effectiveness; Hospitalizations; RotaTeq

Indexed keywords

LIVE VACCINE; ROTAVIRUS VACCINE;

ARTICLE; CHINA; DISEASE SURVEILLANCE; DRUG EFFICACY; HONG KONG; HOSPITALIZATION; HUMAN; IMMUNIZATION; INDIA; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MORTALITY; ROTAVIRUS INFECTION; SOUTH KOREA; TAIWAN; THAILAND; VIRAL GASTROENTERITIS;

ASIA; CHILD, PRESCHOOL; GASTROENTERITIS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SURVIVAL ANALYSIS; VACCINES, ATTENUATED;

EID: 79955949881     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.5.14620     Document Type: Article

References (27)

1. Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009; 200:16-27.
2. Mast TC, DeMuro-Mercon C, Kelly CM, Floyd LE, Walter EB. The impact of rotavirus gastroenteritis on the family. BMC Pediatr 2009; 9:11.
3. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RJ. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72. (Pubitemid 36529515)
4. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200:9-15.
5. Nelson EAS, Bresee JS, Parashar UD, Widdowson MA, Glass RI. Asian Rotavirus Surveillance Network. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 2008; 26:3192-6.
6. Bresee JS, Hummelman E, Nelson EAS, Glass RI. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines. J Infect Dis 2005; 192:1-5.
7. Bresee JS, Fang ZY, Wang B, Nelson EA, Tam J, Soenarto Y, et al. Rotavirus surveillance in Asia: first report from the Asian Rotavirus Surveillance Network. Emerg Infect Dis 2004; 10:988-95. (Pubitemid 38697688)
8. Gentsch JR, Woods PA, Ramachandran M, Das BK, Leite JP, Alfieri A, et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996; 174:30-6.
9. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56. (Pubitemid 40070041)
10. Matthijnssens J, Rahman M, Ciarlet M, et al. Emerging human rotavirus genotypes. In: Palombo E, Kirkwood CD, Editors. Viruses in the Environment. Trivandrum, Kerala, India: Research Signpost 2008; 171-318.
11. Rose J, Singer ME. Projecting vaccine efficacy: accounting for geographic strain variations. Pharmacoeconomics 2008; 26:185-9. (Pubitemid 351271378)
12. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33. (Pubitemid 43048948)
13. Vesikari T, Itzler R, Matson DO, Santosham M, Christie CDC, Coia M, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007; 11:29-35.
14. Vesikari T, Karvonen A, Ferrante SA, Kuter BA, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RotaTeq, up to 3.1 years following the last dose of vaccine [published online ahead of print May 3, 2010]. Pediatr Infect Dis J; DOI: 10.1097/INF.0b013e3181e28e6e.
15. Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, et al. Efficacy, immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007; 119:11-8. (Pubitemid 46397837)
16. Li DD, Liu N, Yu JM, Zhang Q, Cui SX, Zhang DL, et al. Molecular epidemiology of G9 rotavirus strains in children with diarrhoea hospitalized in mainland China from January 2006 to December 2007. Vaccine 2009; 27:40-5.
17. Lo JY, Szeto KC, Tsang DN, Leung KH, Lim WW. Changing epidemiology of rotavirus G-types circulating in Hong Kong, China. J Med Virol 2005; 75:170-3. (Pubitemid 39578805)
18. Kang G, Arora R, Chitambar SD, Deshpande J, Gupte MD, Kulkarni M, et al. Multicenter, hospital-based surveillance of rotavirus disease and strains among Indian children aged <5 years. J Infect Dis 2009; 200:147-53.
19. Lee SY, Hong SK, Lee SG, Suh CI, Park SW, Lee JH, et al. Human rotavirus genotypes in hospitalized children, South Korea, April 2005 to March 2007. Vaccine 2009; 27:97-101.
20. Wu FT, Liang SY, Tsao KC. Hospital-based surveillance and molecular epidemiology of rotavirus infection in Taiwan 2005-2007. Vaccine 2009; 27:50-4.
21. Jiraphongsa C, Bresee JS, Pongsuwanna Y, Kluabwang P, Poonawagul U, Arporntip P, et al. Epidemiology and burden of rotavirus diarrhea in Thailand: results of sentinel surveillance. J Infect Dis 2005; 192:87-93.
22. World Health Organization. Estimated rotavirus death for children under 5 years. Available at: http://www. who.int/immunization-monitoring/burden/ rotavirus- estimates/en/index.html. Accessed September 24, 2009.
23. Curns AT, Coffin F, Glasser JW, Glass RI, Parashar UD. Projected impact of the new rotavirus vaccination program on hospitalizations for gastroenteritis and rotavirus disease among US children <5 years of age during 2006-2015. J Infect Dis 2009; 200:49-56.
24. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010; 201:1617-24.
25. Zaman K, Anh DD, Victor JC, Shin S, Yunus M, Dallas MJ, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615-23.
26. Wang FT, Mast TC, Glass R, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125:208-13.
27. Steele AD, Patel M, Parashar UD, Victor JC, Aguado T, Neuzil KM. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a world health organization-sponsored consultation. J Infect Dis 2009; 200:63-9.